ATE556092T1 - Mittel zur diagnose und therapie von ctcl - Google Patents

Mittel zur diagnose und therapie von ctcl

Info

Publication number
ATE556092T1
ATE556092T1 AT01271393T AT01271393T ATE556092T1 AT E556092 T1 ATE556092 T1 AT E556092T1 AT 01271393 T AT01271393 T AT 01271393T AT 01271393 T AT01271393 T AT 01271393T AT E556092 T1 ATE556092 T1 AT E556092T1
Authority
AT
Austria
Prior art keywords
ctcl
diagnosis
therapy
agents
novel
Prior art date
Application number
AT01271393T
Other languages
English (en)
Inventor
Armand Bensussan
Laurence Boumselle
Martine Bagot
Allessandro Moretta
Original Assignee
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of ATE556092T1 publication Critical patent/ATE556092T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01271393T 2000-12-18 2001-12-18 Mittel zur diagnose und therapie von ctcl ATE556092T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00403580 2000-12-18
PCT/EP2001/015417 WO2002050122A2 (en) 2000-12-18 2001-12-18 Means for the diagnosis and therapy of ctcl

Publications (1)

Publication Number Publication Date
ATE556092T1 true ATE556092T1 (de) 2012-05-15

Family

ID=8173990

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01271393T ATE556092T1 (de) 2000-12-18 2001-12-18 Mittel zur diagnose und therapie von ctcl

Country Status (9)

Country Link
US (4) US7399595B2 (de)
EP (1) EP1343822B1 (de)
JP (3) JP2004528824A (de)
AT (1) ATE556092T1 (de)
AU (2) AU2002219229B2 (de)
CA (1) CA2432036C (de)
DK (1) DK1343822T3 (de)
ES (1) ES2387969T3 (de)
WO (1) WO2002050122A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004528824A (ja) * 2000-12-18 2004-09-24 アーンスティテュ ナシオナール ド ラ サント エ ド ラ ルシェルシェ メディカル（イー．エンヌ．エス．ウー．エール．エンム．） 皮膚ｔ細胞リンパ腫（ｃｔｃｌ）の新規な診断及び治療法
EP2292264A3 (de) 2003-07-24 2012-12-19 Innate Pharma Methoden und Zusammensetzungen zur Erhöhung der Wirksamkeit von therapeutischen Antikörper unter Verwendung von Verbindungen, die NK-Zellen potenzieren
DK1773884T3 (da) 2004-08-03 2012-05-21 Innate Pharma Terapeutiske og diagnostiske fremgangsmåder og sammensætninger til targeting af 4ig-b7-h3 og dets tilsvarende nk-celle-receptor
MX2007007935A (es) * 2004-12-28 2007-12-06 Innate Pharma Sa Anticuerpos monoclonales contra nkg2a.
JP5419067B2 (ja) * 2005-10-14 2014-02-19 イナート・ファルマ・ソシエテ・アノニム 増殖性障害を処置するための組成物および方法
AU2007276294B2 (en) 2006-06-30 2012-11-29 Novo Nordisk A/S Anti-NKG2A antibodies and uses thereof
US7917085B2 (en) * 2007-11-09 2011-03-29 Research In Motion Limited System and method for blocking devices from a carrier network
CN101952317B (zh) 2008-01-24 2015-07-22 诺沃-诺迪斯克有限公司 人化抗-人nkg2a单克隆抗体
US20110091482A1 (en) * 2008-04-11 2011-04-21 The Regents Of The University Of Colorado, A Body Corporate Expression of kir in human cancer cells as a biomarker for immuno-escape and cancer metastasis
US9181341B2 (en) * 2009-01-19 2015-11-10 Innate Pharma Anti-KIR3D antibodies
WO2011086179A1 (en) 2010-01-15 2011-07-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosis and treatment of cutaneous t cell lymphomas
US9224537B2 (en) 2011-05-31 2015-12-29 Indian Institute Of Technology Madras Electrode and/or capacitor formation
MX342131B (es) 2011-06-17 2016-09-14 Novo Nordisk As Eliminacion selectiva de celulas erosivas.
US9024609B2 (en) * 2012-07-11 2015-05-05 Pai Capital Llc Circuit and method for providing hold-up time in a DC-DC converter
CN104640880B (zh) * 2012-09-19 2020-06-09 先天制药公司 Kir3dl2结合剂
WO2014044681A1 (en) * 2012-09-19 2014-03-27 Innate Pharma Kir3dl2 binding agents
DK2941233T3 (da) * 2013-01-07 2020-10-19 Univ Pennsylvania Sammensætninger og fremgangsmåder til behandling af kutant T-celle-lymfom
WO2014124267A1 (en) 2013-02-07 2014-08-14 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Method for diagnosis, prognosis and determination of treatment for cutaneous t-cell lymphoma
ES2878749T3 (es) 2013-02-20 2021-11-19 Innate Pharma Un compuesto que se une específicamente a KIR3DL2 para el uso en el tratamiento de linfoma de células T periférico
JPWO2014189138A1 (ja) * 2013-05-23 2017-02-23 Ｉｄａｃセラノスティクス株式会社 免疫不全ウイルス感染の治療又は予防剤
JP6865582B2 (ja) * 2013-05-29 2021-04-28 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｋｉｒ３ｄｌ２は皮膚及び非皮膚末梢ｔ細胞リンパ腫のサブセットをそれぞれ予防及び治療するために有用なバイオマーカー及び治療標的である
WO2015136052A1 (en) 2014-03-14 2015-09-17 Innate Pharma Humanized antibodies with increased stability
WO2018073363A1 (en) 2016-10-21 2018-04-26 Innate Pharma Treatment with anti-kir3dl2 agents
WO2020152081A1 (en) 2019-01-22 2020-07-30 Innate Pharma Treatment of t cell lymphoma
AU2022255908A1 (en) 2021-04-05 2023-10-05 Innate Pharma Immunohistochemistry methods and kir3dl2-specific reagents

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2104526C1 (ru) * 1995-05-05 1998-02-10 Эммануил Маркович Коган Способ диагностики т-клеточных лимфом кожи
JP2004528824A (ja) * 2000-12-18 2004-09-24 アーンスティテュ ナシオナール ド ラ サント エ ド ラ ルシェルシェ メディカル（イー．エンヌ．エス．ウー．エール．エンム．） 皮膚ｔ細胞リンパ腫（ｃｔｃｌ）の新規な診断及び治療法

Also Published As

Publication number Publication date
AU2002219229B9 (en) 2002-07-01
AU2002219229B2 (en) 2007-12-20
JP2008261875A (ja) 2008-10-30
WO2002050122A2 (en) 2002-06-27
CA2432036A1 (en) 2002-06-27
US8268308B2 (en) 2012-09-18
CA2432036C (en) 2018-05-01
WO2002050122A3 (en) 2003-04-10
US7399595B2 (en) 2008-07-15
US7919085B2 (en) 2011-04-05
US20110151472A1 (en) 2011-06-23
US20080274468A1 (en) 2008-11-06
EP1343822B1 (de) 2012-05-02
JP2004528824A (ja) 2004-09-24
DK1343822T3 (da) 2012-08-13
US20050074761A1 (en) 2005-04-07
JP5134445B2 (ja) 2013-01-30
ES2387969T3 (es) 2012-10-04
US8518655B2 (en) 2013-08-27
AU1922902A (en) 2002-07-01
JP2008289489A (ja) 2008-12-04
US20120329063A1 (en) 2012-12-27
EP1343822A2 (de) 2003-09-17

Similar Documents

Publication Publication Date Title
ATE556092T1 (de) Mittel zur diagnose und therapie von ctcl
BR0111125A (pt) Moléculas de ácido nucléico de nrg-2, polipeptìdeos, e métodos diagnóstico e terapêuticos
NO20041917L (no) Spesifikke midler som binder humant angiopoietin-2
DE69739856D1 (de) Agonisten für den rezeptor des hepatozyten-wachstumsfaktors und deren anwendungen
BR0011838A (pt) Elementos misturadores estáticos empilhados
SE9802729D0 (sv) Novel Compounds
DE602004014361D1 (de) Verwendung von oxazolidinon-chinolin-hybrid-antibiotika zur behandlung von anthrax und anderen infektionen
EP1505990A4 (de) Verfahren zur behandlung von hepatitis
DE60138715D1 (de) Tnf-rezeptor-ähnliche moleküle und deren anwendungen
EP1465990A4 (de) Gestutzes lysostaphin-molekül mit verbesserter staphylolytischer wirkung
ATE319439T1 (de) Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd
ES2168361T3 (es) Secuencias de adn para metaloproteasas de la matriz, su preparacion y empleo.
EP1423137A4 (de) Lipopeptid-stereoisomere, verfahren zu ihrer herstellung und nützliche zwischenprodukte
NO20055741D0 (no) Nye kjemiske forbindelser
DE60234354D1 (de) Piperazinon-verbindungen als antitumorale und krebsbekämpfende mittel
DE60115349D1 (de) Polymorphismen im Gen für den humanen organischen Anionentransporter C (OATP-C)
ATE483714T1 (de) Podophyllotoxine als antiproliferative mittel
ATE383874T1 (de) Perylenequinonen zur anwendung als sonosensitizer
DK1406927T3 (da) Glycopeptider, fremstilling og anvendelse deraf til diagnosticering eller terapeutisk behandling af dissemineret sklerose
ATE545421T1 (de) Pharmazeutisches präparat zur behandlung von parasitären tropenkrankheiten enthaltend diminazen-di-aceturat
ATE374260T1 (de) Asthma-assoziiertes gen
DE50004023D1 (de) 1,4-dioxacycloalkan-2-one und 1,4-dioxacycloalken-2-one
DE50215004D1 (de) Organische verbindungen mit biologischer wirkung als thrombinhemmer und ihre verwendung
ATE390435T1 (de) Zusammensetzungen und verfahren zur diagnose und behandlung von diabetes, insulinresistenz und dyslipidämie
ATE442122T1 (de) Dentalmaterial mit bakteriostatischen und/oder bakteriziden substanzen